To improve the prognosis of patients with this PCa subtype, Brandon A. Mahal et al. suggested that the addition of docetaxel to the standard of care treatment for nonmetastatic PCa patients, who are in otherwise good health with PSA <4 ng/mL and GS ≥ 8, was associated with a significant reduction in PCSM[14]. Here, KLK3 is linked to posterior cortical atrophy.